NCT01423032View on ClinicalTrials.gov

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

bendamustine

100 mg/m² iv, day 1+2, q4w

DRUG

Fludarabine

25 mg/m² iv, days 1-5, q4w

Trial Locations (1)

D-51375

Prof. Dr. Norbert Niederle, Leverkusen

All Listed Sponsors
collaborator

Klinikum Leverkusen gGmbH

UNKNOWN

collaborator

ribosepharm GmbH

UNKNOWN

collaborator

Mundipharma Research GmbH & Co KG

INDUSTRY

lead

WiSP Wissenschaftlicher Service Pharma GmbH

OTHER

NCT01423032 - Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter